News and Reports
-
Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
21 July 2017Download -
Amphora Medical Closes $35.5 Million Series B Financing
20 July 2017Download -
Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and Endpoints in Acute Bacterial Skin Infections
17 July 2017Download -
Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017
31 May 2017Download -
Formation Biologics Announces Dosing of First Patient in a Phase I/IIa Trial of AVID 100 and Closing of Series B Financing
15 May 2017Download -
Amicus SA Receives Support and Growth Capital from HBM Healthcare Investments
27 April 2017Download -
Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia
3 April 2017Download -
Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne
27 March 2017Download -
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
7 March 2017Download -
Vascular Dynamics? Announces Expedited Access Pathway Designation by FDA for MobiusHD® to Accelerate US Access for Treatment of Resistant Hypertension
1 February 2017Download -
DePuy Synthes Acquires Interventional Spine Expandable Cage Technology to Accelerate Growth in Spine
3 January 2017Download -
ARMO BioSciences? Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the U.S. FDA for the Treatment of Pancreatic Cancer
14 November 2016Download -
Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals
1 November 2016Download -
Curetis Announces Positive Top Line Data from U.S. FDA Trial
25 October 2016Download -
Gynesonics completes enrollment in SONATA FDA trial for treatment of uterine fibroids
18 October 2016Download -
ObsEva starts Phase IIb EDELWEISS study in endometriosis
11 October 2016Download -
Advanced Accelerator Applications S.A. Announces Pricing of $150 Million Public Offering of American Depositary Shares
5 October 2016Download -
Advanced Accelerator Applications Reports 24.4% Sales Growth in the Second Quarter of 2016
31 August 2016Download -
Paratek Initiates Phase 3 Study of Oral-Only Omadacycline in ABSSSI
15 August 2016Download -
ObsEva initiates Phase 1 for OBE022 in Preterm Labor
28 July 2016Download -
Cell Medica Acquires Delenex Therapeutics
12 July 2016Download -
ObsEva Receives FDA Clearance to Initiate Phase 2b Study of OBE2109 in Endometriosis
6 July 2016Download -
AnaptysBio Initiates Multiple Ascending Dose Cohorts in ANB020 Phase 1 Clinical Trial
6 July 2016Download -
Advanced Accelerator Applications Announces FDA Priority Review for Lutathera
27 June 2016Download -
Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections
16 June 2016Download